124 related articles for article (PubMed ID: 8584651)
1. Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice.
Sziráki I; Kardos V; Patthy M; Gaál J; Arányi P; Kollár E; Tömösközi Z; Király I
Prog Brain Res; 1995; 106():155-71. PubMed ID: 8584651
[No Abstract] [Full Text] [Related]
2. The effects of deprenyl on methamphetamine-induced dopamine depletions.
Johnson SK; Medina D; Wagner GC
J Neural Transm Gen Sect; 1992; 89(1-2):123-7. PubMed ID: 1418863
[TBL] [Abstract][Full Text] [Related]
3. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
Wiener HL; Hashim A; Lajtha A; Sershen H
J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
[TBL] [Abstract][Full Text] [Related]
4. Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice.
Vaglini F; Fascetti F; Tedeschi D; Cavalletti M; Fornai F; Corsini GU
Neurodegeneration; 1996 Jun; 5(2):129-36. PubMed ID: 8819133
[TBL] [Abstract][Full Text] [Related]
5. Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice.
Fung YK; Fiske LA; Lau YS
Gen Pharmacol; 1991; 22(4):669-72. PubMed ID: 1936899
[TBL] [Abstract][Full Text] [Related]
6. L-deprenyl in prevention of MPTP induced depletion of striatal enkephalins in mice.
Sheng JG; Xu DL; Yu HZ
Chin Med J (Engl); 1988 Apr; 101(4):292-4. PubMed ID: 3138091
[No Abstract] [Full Text] [Related]
7. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
[TBL] [Abstract][Full Text] [Related]
8. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
Rothblat DS; Schneider JS
Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
[TBL] [Abstract][Full Text] [Related]
9. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
[TBL] [Abstract][Full Text] [Related]
10. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
Rothblat DS; Schneider JS
Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of L-deprenyl on MPP+- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens.
Wu WR; Zhu ZT; Zhu XZ
Life Sci; 2000 Jun; 67(3):241-50. PubMed ID: 10983868
[TBL] [Abstract][Full Text] [Related]
12. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
13. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.
Obuchowicz E; Antkiewicz-Michaluk L; Romańska I; Herman ZS
J Neural Transm (Vienna); 2003 Dec; 110(12):1375-91. PubMed ID: 14666410
[TBL] [Abstract][Full Text] [Related]
14. A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity.
Fuller RW; Hemrick-Luecke SK
J Pharm Pharmacol; 1989 Jul; 41(7):492-3. PubMed ID: 2570859
[TBL] [Abstract][Full Text] [Related]
15. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
16. [The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Nakashima H; Asari S; Nishimoto A; Goldstein M
No To Shinkei; 1991 Apr; 43(4):357-61. PubMed ID: 1909537
[TBL] [Abstract][Full Text] [Related]
17. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
Castagnoli K; Palmer S; Castagnoli N
Neurobiology (Bp); 1999; 7(2):135-49. PubMed ID: 10591048
[TBL] [Abstract][Full Text] [Related]
19. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
Perez V; Unzeta M
Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
[TBL] [Abstract][Full Text] [Related]
20. Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity.
Gong L; Daigneault EA; Acuff RV; Kostrzewa RM
Neuroreport; 1991 Sep; 2(9):544-6. PubMed ID: 1751810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
